52 Week Range
As of on the NASDAQ ∙ Minimum 15 minute delay
3M AVG Volume
52 Week High
52 Week Low
Shares Out (MIL)
Market Cap (MIL)
Dividend (Yield %)
Sanofi Says Dupixent Reduces Severe Asthma Attacks in Children
Regeneron Says Dupixent (Dupilumab) Significantly Reduced Severe Asthma Attacks In Children
Sanofi: Libtayo Monotherapy Increases Overall Survival In First-Line Advanced Non-Small Cell Lung Cancer
Regeneron Pharmaceuticals, Inc. is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases. The Company's marketed products include EYLEA (aflibercept) Injection, Praluent (alirocumab) Injection, ARCALYST (rilonacept) Injection for Subcutaneous Use, Kevzara (sarilumab) Solution for Subcutaneous Injection and ZALTRAP (ziv-aflibercept) Injection for Intravenous Infusion. As of December 31, 2016, the Company had 16 product candidates in clinical development, which consisted of a Trap-based clinical program and 15 fully human monoclonal antibody product candidates.
Biotechnology & Drugs
777 Old Saw Mill River Rd
P. Roy Vagelos
Chairman of the Board, Director
Leonard S. Schleifer
President, Chief Executive Officer, Director
George D. Yancopoulos
President, Chief Scientific Officer, Director
Robert E. Landry
Chief Financial Officer, Executive Vice President - Finance
Joseph J. LaRosa
Executive Vice President, General Counsel, Secretary
Price To Earnings (TTM)
Price To Sales (TTM)
Price To Book (MRQ)
Price To Cash Flow (TTM)
Total Debt To Equity (MRQ)
LT Debt To Equity (MRQ)
Return on Investment (TTM)
Return on Equity (TTM)
The U.S. Food and Drug Administration on Wednesday approved Regeneron Pharmaceuticals' triple antibody cocktail as the first Ebola virus treatment, lending validation to similar drugs being developed for COVID-19.
U.S. President Donald Trump is no longer capable of spreading the novel coronavirus and can attend a town hall on Thursday without putting others at risk, top U.S. public health official Anthony Fauci said in an interview with CBS Evening News.
The U.S. Food and Drug Administration on Wednesday approved Regeneron Pharmaceuticals' Inmazeb as the first FDA-approved treatment for the Ebola virus infection in adults and children.
(This Oct. 13 story corrects the headline and paragraphs 1 and 9 to show the federal government, not Eli Lilly, made the decision to pause a clinical trial of the company’s antibody drug)
The U.S. government expects to be able to provide at no cost more than 1 million doses of antibody treatments for COVID-19 similar to the one President Donald Trump received to treat his illness, according to a top U.S. health official on Friday.
U.S. President Donald Trump said on Friday he is working to get coronavirus antibody drugs developed by Regeneron Pharmaceuticals Inc and Eli Lilly and Co approved quickly and out to hospitals after his own positive coronavirus treatment experience.
A top U.S. health official said on Friday that the government expects to have access to over 1 million doses of Regeneron Pharmaceutical Inc's and Eli Lilly's & Co's antibody treatments for COVID-19 in 2020.
Top U.S. infectious diseases expert Dr. Anthony Fauci said on Thursday that President Donald Trump's health was likely helped by an experimental therapy made by Regeneron Inc in which he received antibodies to fight the disease.
Patients are asking to join clinical trials of antibody-based COVID-19 drugs after U.S. President Donald Trump was treated last week with an experimental therapy from Regeneron Pharmaceuticals Inc <REGN.O>, and on Wednesday he promised to make it free to Americans while...
Patients are asking to join clinical trials of antibody-based COVID-19 drugs after U.S. President Donald Trump was treated last week with an experimental therapy from Regeneron Pharmaceuticals Inc, and on Wednesday he promised to make it free to Americans while touting its...
President Donald Trump, in a video posted on Twitter on Wednesday, credited Regeneron Pharmaceuticals Incand Eli Lilly and Co therapeutics for his recovery and said he wanted to make them more widely available.
* Indexes up: Dow 1.3%, S&P 1.4%, Nasdaq 1.8% (Updates to late afternoon)
President Donald Trump has been treated with an experimental antibody cocktail for COVID-19 and is moving to a military hospital as a precautionary measure, White House officials said on Friday.
President Donald Trump "remains fatigued but in good spirits" and is receiving treatment for the new coronavirus, the president's physician, Dr. Sean Conley, said in a statement on Friday.
Regeneron Pharmaceuticals Inc on Tuesday said its experimental two-antibody cocktail reduced viral levels and improved symptoms in non-hospitalized COVID-19 patients, enhancing its chances of becoming a treatment for the disease that has killed over a million people worldwide...
Novartis's Beovu matched Regeneron's Eylea in vision clarity scores for a blindness-causing eye disease, the Swiss drugmaker said on Monday, after early safety stumbles for the medicine in another condition caused disappointing early sales.
The world's largest randomised trial of potential medicines for COVID-19 is to add Regeneron's experimental antiviral antibody cocktail REGN-COV2 to the drugs it is testing in patients hospitalised with the disease.
Novartis on Monday said its eye drug Beovu matched rival Eylea from Regeneron in visual acuity at one year in patients with diabetic macular edema (DME), as the Swiss drugmaker seeks to regain momentum with the drug after early safety stumbles.
Regeneron Pharmaceuticals said on Wednesday it expects to report biomarker data for its COVID-19 antibody cocktail by the end of this month.
The rheumatoid arthritis drug Kevzara has failed as a COVID-19 treatment, French drugmaker Sanofi said on Tuesday following a similar flop of a Roche product.
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.